LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, progressing at a CAGR of close to 6% during the forecast period.
Read the 157-page research report with TOC on "Chronic Myelogenous Leukemia (CML) therapeutics Market Analysis Report by product (targeted therapy, chemotherapy, and immunotherapy), and geography (North America, Europe, Asia, and ROW) 2019 - 2023". Request a Free Sample Report.
The market is driven by strategic alliances. In addition, the advent of novel therapies is expected to further boost the growth of the chronic myelogenous leukemia (CML) therapeutics market.
The market has witnessed multiple strategic alliances in recent years. Vendors are increasingly collaborating to expand their distribution networks and overcome challenges associated with the high cost of R&D of CML therapeutics. These alliances include license agreement among educational institutions, support groups, pharma, and diagnostic companies. Thus, effective alliances among companies and institutes will drive the growth of the market during the forecast period.
The strong prevalence of CML at a global level has necessitated the development of novel therapies. Although many therapeutics are approved for several cancers, the treatment landscape of advanced cancers still has a scope of improvement. Most of the available therapeutics have adverse effects, which is leading to low patient adherence. Thus, extensive research is being carried out by vendors to introduce novel therapies for the treatment of CML. This will have a key impact on the growth of the CML therapeutics market.
For More Information: Request Free Sample Pages
The report includes detailed profiles of the leading companies & prominent vendors of the market:
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Mylan NV
Market Segmentation by Product:
The chronic myelogenous leukemia (CML) therapeutics market can be broadly categorized into the following segments:
- Targeted therapy
Key Regions for the Chronic Myelogenous Leukemia (CML) Therapeutics Market:
Featuring a breakdown of region-wise market shares until 2019.
- North America
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report.
Related Reports on Healthcare are:
Kidney Stones Management Devices Market – Global Kidney Stones Management Devices Market by procedure (URS, ESWL, and PCNL) and geography (Asia, Europe, North America, and ROW).
Polycystic Kidney Disease Drugs Market – Global Polycystic Kidney Disease Drugs Market by type (ADPKD and ARPKD) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.